Biofrontera AG (BFRA): Price and Financial Metrics

Biofrontera AG (BFRA): $6.69

-0.18 (-2.62%)

POWR Rating

Component Grades














  • BFRA scores best on the Value dimension, with a Value rank ahead of 85.47% of US stocks.
  • BFRA's strongest trending metric is Momentum; it's been moving down over the last 173 days.
  • BFRA's current lowest rank is in the Quality metric (where it is better than 18.06% of US stocks).

BFRA Stock Summary

  • With a one year PEG ratio of 721.22, Biofrontera AG is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.74% of US stocks.
  • With a year-over-year growth in debt of 924.7%, Biofrontera AG's debt growth rate surpasses 98.39% of about US stocks.
  • Revenue growth over the past 12 months for Biofrontera AG comes in at 375.12%, a number that bests 98.1% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to BFRA, based on their financial statements, market capitalization, and price volatility, are GVP, FRAF, MCBC, FRME, and RGA.
  • BFRA's SEC filings can be seen here. And to visit Biofrontera AG's official web site, go to

BFRA Stock Price Chart Interactive Chart >

Price chart for BFRA

BFRA Price/Volume Stats

Current price $6.69 52-week high $55.00
Prev. close $6.87 52-week low $4.67
Day low $6.62 Volume 11,500
Day high $6.89 Avg. volume 82,502
50-day MA $5.98 Dividend yield N/A
200-day MA $7.02 Market Cap 189.72M

Biofrontera AG (BFRA) Company Bio

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Biofrontera AG was founded in 1997 and is based in Leverkusen, Germany.

BFRA Latest News Stream

Event/Time News Detail
Loading, please wait...

BFRA Latest Social Stream

Loading social stream, please wait...

View Full BFRA Social Stream

Latest BFRA News From Around the Web

Below are the latest news stories about Biofrontera AG that investors may wish to consider to help them evaluate BFRA as an investment opportunity.

Biofrontera reports prelim product sales revenue growth of 108% in May

For May 2021, Biofrontera ([[BFRA]] +1.0%) reported prelim revenue from product sales of €2.44M compared to €1.17M in year ago quarter.Out of the total, revenues from product sales in the U.S. increased 174% while Germany revenues dropped 21%; rest of Europe revenue surged 1,041%....

Seeking Alpha | June 7, 2021

Biofrontera reports preliminary revenue for the month of May 2021

Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of May 2021. The Company’s preliminary, unaudited revenue from product sales in May 2021 amounted to approximately EUR 2,437 thousand, compared to EUR 1,172 thousand in May 2020, an increase of 108%. Preliminary revenues from product sales in the US were around E

Yahoo | June 7, 2021

Biofrontera AG to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 12, 2021 / Biofrontera AG (NASDAQ:BFRA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 8:00 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.

Yahoo | May 12, 2021

Biofrontera reports Q1 2021 financial results

Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021. Q1 2021 key financial figures and business performance In EUR thousands3M 20213M 2020ChangeRevenue5,479 6,473 (15)%Gross profit on sales4,578 5,674 (19)%Research and development costs(1,317)(1,311)0%General and administrative costs(2,538)(2,232)14%Sales and marketing costs(4,813)(8,698)(45)%Profit (loss) on operations(4,089)(6,567)(38)%EBITDA(3,158)(2,645)19%EBIT(3,971)(5,555)(29)%Earnings (loss) before tax(4,876)(5,498)(11)%Earnings (loss) after tax(4,877)(5,499)(11)% Biofrontera's business performance was encouragingly positive afte...

Yahoo | May 11, 2021

Biofrontera AG: First quarter conference call to be held on May 12, 2021

Leverkusen, Germany, May 03, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first quarter 2021 on Tuesday, May 11, 2021. Conference calls for shareholders and interested investors will be held on Wednesday, May 12, 2021, at the following times: In German, May 12, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: +49 69201744220Conference code: 60386865# In English, May 12, 2021 at 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 52497289# Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.-End- Biofrontera AGPamela Keck, Head of Investor...

Yahoo | May 3, 2021

Read More 'BFRA' Stories Here

BFRA Price Returns

1-mo 23.09%
3-mo 12.44%
6-mo -4.56%
1-year -4.97%
3-year -48.81%
5-year N/A
YTD -8.23%
2020 N/A
2019 0.00%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.6891 seconds.